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Chronic pain such as neuropathic pain, osteoarthritic pain,
or abnormal pain associated with neurological diseases rep-
resents a debilitating condition which strongly affects the
quality of life of patients. The mechanisms at the basis of the
induction and maintenance of chronic pain are still poorly
understood. Thus, an appropriate therapy for chronic pain is
not yet available and there are many failures in treatments.
Recent evidence suggests a role for central and periph-
eral immune cells (microglia, macrophages, astrocytes, mast
cells, and T-cells) in the initiation of peripheral and central
sensitization. They mediate the plastic changes occurring
within pain pathways that result in sensory dysfunctions and
behavioural correlates, such as thermal/mechanical hyperal-
gesia and tactile allodynia. Because of the complex molecular
and cellular mechanisms involved in the neuropathic pain
induction and maintenance, several mediators have been
demonstrated to be crucial in its induction and maintenance
in the last years.
Historically the NMDA receptor for glutamate has been
deeply investigated for the spinal wind-up occurring in the
establishment of tactile allodynia. The role of the NMDA
NR2B subunit as well as a possible pharmacological activity
of its natural agonist, the D-aspartic acid, has been further
clarified in this issue. More recent data suggest a role for
lipid-mediated pathways such as sphingosine-1-phosphate or
endocannabinoid systems in the modulation of spinal and
supraspinal events associated with peripheral neuropathy
[1, 2]. Besides the endocannabinoids also the “so-called”
endocannabinoid-like molecules such as palmitoylethanola-
mide and oleoylethanolamide (PEA and OEA) have been
demonstrated to be potentially useful to treat neuropathic
pain-associated allodynia and hyperalgesia [3–5].
In this issue further investigations on the possible alter-
ations in the anandamide metabolism in the development of
neuropathic pain have been addressed. Moreover, the pos-
sible use of the palmitoylethanolamide in the delay of mor-
phine tolerance has also been suggested. In this special issue,
focused on further understanding of themolecular and cellu-
lar mechanisms at the basis of the chronic neuropathic pain,
several other neuromodulatory systems have been analyzed.
A possible role of a new class of chemokines, the proki-
neticins, of the somatostatin receptor activation, of the noci-
ceptin/orphanin, and of the mTOR pathway in neuropathic
pain mechanisms has been further elucidated. Moreover, the
possible use of a still far stem cells therapy has been reviewed
in the issue.
Nowadays a pivotal role of microglia in the establishment
of tactile allodynia is confirmed.Themicroglia activation and
recruitment seem to be highly regulated by purinergic sys-
tem. Indeed, it has been highlighted that the abnormal ATP
release in the dorsal horn of the spinal cord is responsible for
the BDNF release from microglia through a mechanism
mediated by P
2
X
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which, in turn, causes the shift in neuronal
anion gradient [6]. Moreover, also a role for the P
2
X
7
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microglial release of IL-1𝛽 and other proinflammatory
molecules such as cathepsin S has been demonstrated [7].The
role of the purinergic system in the regulation of glial and
microglial cells has been extensively reviewed in the paper by
G. Magni and S. Ceruti.
In conclusion, we hope that the readers will find in
this special issue a discreet panoramic view of the puzzling
mechanisms involved in chronic pain development.
Livio Luongo
Marzia Malcangio
Daniela Salvemini
Katarzyna Starowicz
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